Nothing Special   »   [go: up one dir, main page]

DK1045918T3 - G protein-relaterede kinasemutanter i essentiel hypertension - Google Patents

G protein-relaterede kinasemutanter i essentiel hypertension

Info

Publication number
DK1045918T3
DK1045918T3 DK99902201T DK99902201T DK1045918T3 DK 1045918 T3 DK1045918 T3 DK 1045918T3 DK 99902201 T DK99902201 T DK 99902201T DK 99902201 T DK99902201 T DK 99902201T DK 1045918 T3 DK1045918 T3 DK 1045918T3
Authority
DK
Denmark
Prior art keywords
essential hypertension
present
protein
related kinase
kinase mutants
Prior art date
Application number
DK99902201T
Other languages
English (en)
Inventor
Robin Felder
Pedro Jose
Original Assignee
Pedro Jose
Felder Robin A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pedro Jose, Felder Robin A filed Critical Pedro Jose
Application granted granted Critical
Publication of DK1045918T3 publication Critical patent/DK1045918T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/054Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
    • A01K2217/056Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to mutation of coding region of the transgene (dominant negative)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
DK99902201T 1998-01-12 1999-01-12 G protein-relaterede kinasemutanter i essentiel hypertension DK1045918T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7119998P 1998-01-12 1998-01-12
US9827998P 1998-08-28 1998-08-28
PCT/US1999/000663 WO1999035279A1 (en) 1998-01-12 1999-01-12 G protein-related kinase mutants in essential hypertension

Publications (1)

Publication Number Publication Date
DK1045918T3 true DK1045918T3 (da) 2008-12-08

Family

ID=26751950

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99902201T DK1045918T3 (da) 1998-01-12 1999-01-12 G protein-relaterede kinasemutanter i essentiel hypertension

Country Status (9)

Country Link
US (3) US6660474B1 (da)
EP (2) EP2009109A1 (da)
JP (2) JP4652566B2 (da)
AT (1) ATE405661T1 (da)
AU (1) AU2223899A (da)
CA (1) CA2318479C (da)
DE (1) DE69939367D1 (da)
DK (1) DK1045918T3 (da)
WO (1) WO1999035279A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002035923A1 (en) * 2000-10-31 2002-05-10 Duke University Hypertension
WO2002103020A1 (en) * 2001-06-15 2002-12-27 Takeda Chemical Industries, Ltd. Novel disease-associated gene and use thereof
AU2002358267A1 (en) * 2001-12-19 2003-07-09 Millennium Pharmaceuticals, Inc. Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908
WO2005093096A1 (es) * 2004-03-29 2005-10-06 Universitat Pompeu Fabra Método y kit para la detección del riesgo de padecer hipertensión
WO2005114195A1 (en) * 2004-05-21 2005-12-01 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 4 (grk4)
CN100465288C (zh) * 2005-08-10 2009-03-04 中国医学科学院阜外心血管病医院 检测与人类原发性高血压相关的grk4基因多态的方法
US20080268442A1 (en) * 2007-04-24 2008-10-30 Igd Intel, Llc Method and system for preparing a blood sample for a disease association gene transcript test
US20090125244A1 (en) * 2007-11-09 2009-05-14 Igd Intel Llc Broad-based neurotoxin-related gene mutation association from a gene transcript test
US8135545B2 (en) 2007-11-09 2012-03-13 Iverson Genetic Diagnostics, Inc. System and method for collecting data regarding broad-based neurotoxin-related gene mutation association
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
US9657348B2 (en) 2013-01-13 2017-05-23 Atrogi Ab Method of screening compounds for the treatment of diabetes
WO2015090350A1 (en) 2013-12-16 2015-06-25 Atrogi Ab A screening method, a kit, a method of treatment and a compound for use in a method of treatment
CN105296488B (zh) * 2015-12-02 2018-05-01 中国人民解放军第三军医大学第三附属医院 超声微泡介导的siRNA干扰GRK4在靶向调节尿钠排泄及血压水平中的应用
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
CN107881226A (zh) * 2017-10-30 2018-04-06 广东药科大学 Scad基因或scad蛋白在制备防治血管重构和重大血管疾病药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
EP0289121B1 (en) 1987-05-01 1995-12-27 Stratagene Mutagenesis testing using transgenic non-human animals carrying test DNA sequences
US5221778A (en) 1988-08-24 1993-06-22 Yale University Multiplex gene regulation
US5098890A (en) 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5087617A (en) 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5175383A (en) 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
AU646877B2 (en) 1990-06-15 1994-03-10 Scios Nova Inc. Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5288846A (en) 1990-10-19 1994-02-22 The General Hospital Corporation Cell specific gene regulators
DE4126968A1 (de) 1991-08-14 1993-02-18 Detlev Prof Dr Med Ganten Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
PT620849E (pt) 1992-01-07 2003-11-28 Elan Pharm Inc Modelos animais transgenicos para a doenca de alzheimer
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California TRANSGENIC NON-HUMAN ANIMALS WITH TARGETED INTERRUPTED TRANSDUCTION GENES IN LYMPHOCYTES.
CA2151585A1 (en) 1992-12-14 1994-06-23 Benjamin Weiss Administration of oligonucleotides antisense to dopamine receptor mrna for diagnosis and treatment of neurological pathologies
WO1994023049A2 (en) 1993-04-02 1994-10-13 The Johns Hopkins University The introduction and expression of large genomic sequences in transgenic animals
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US5834248A (en) 1995-02-10 1998-11-10 Millennium Pharmaceuticals Inc. Compositions and methods using rchd534, a gene uregulated by shear stress
NO953680D0 (no) 1995-09-18 1995-09-18 Hans Prydz Cellesyklusenzymer
CA2236825A1 (en) 1995-11-21 1997-05-29 Icn Pharmaceuticals, Inc. Inhibition of tumor growth by antisense oligonucleotides for il-8 and il-8 receptor
US5856099A (en) 1996-05-21 1999-01-05 Isis Pharmaceuticals, Inc. Antisense compositions and methods for modulating type I interleukin-1 receptor expression

Also Published As

Publication number Publication date
EP1045918A1 (en) 2000-10-25
CA2318479A1 (en) 1999-07-15
JP4652566B2 (ja) 2011-03-16
JP2011036253A (ja) 2011-02-24
JP2002508157A (ja) 2002-03-19
DE69939367D1 (de) 2008-10-02
ATE405661T1 (de) 2008-09-15
AU2223899A (en) 1999-07-26
WO1999035279A1 (en) 1999-07-15
CA2318479C (en) 2009-03-24
US6660474B1 (en) 2003-12-09
JP5340242B2 (ja) 2013-11-13
US20050089871A1 (en) 2005-04-28
US20100313286A1 (en) 2010-12-09
EP1045918B1 (en) 2008-08-20
EP1045918A4 (en) 2003-10-08
EP2009109A1 (en) 2008-12-31
US9074016B2 (en) 2015-07-07

Similar Documents

Publication Publication Date Title
DK1045918T3 (da) G protein-relaterede kinasemutanter i essentiel hypertension
ATE412891T1 (de) Verbessertes toxizität-screening verfahren
ECSP055975A (es) Tinturas de cianina hidrofílicas, reactivas con tiol y conjugados de las mismas con biomoléculas para diagnóstico por fluorescencia
ATE251658T1 (de) Wasserlösliche rhodaminfarbstoffe und ihre konjugate
ATE248175T1 (de) Epothilonderivate und ihre verwendung als antitumormittel
IL140622A0 (en) Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
EA200300580A1 (ru) Соединения лактама
TR200102026T2 (tr) Dopamin-D3-reseptör afinitesine sahip triazol bileşikleri.
ATE301122T1 (de) Kernerweiterte perylenbisimide und ihre verwendung als fluoreszenzfarbstoffe
ATE37375T1 (de) Phosphonyl-hydroxyacyl-aminosaeure-derivate und ihre verwendung als antihypertensiva.
EP1687283A4 (en) PROCESS AND COMPOSITION FOR DETERMINING FK 506
CA2439222A1 (en) Identification of partial agonists of the a2a adenosine receptor
TR200101663T2 (tr) Pro-kollajen c-proteinaz inhibitörleri
TR200002380T2 (tr) Yeni triazolo (4,5-d) pirimidin bileşikleri
BRPI0412716A (pt) antagonistas de receptor muscarìnico de acetilcolina
ATE284407T1 (de) Pyrimidinderivate als markierte bindungspartner
BRPI0412679A (pt) antagonistas de receptor muscarìnico de acetilcolina
MEP56408A (en) Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
BR9902084A (pt) Heterociclos.
ES2185002T3 (es) Metodos y composiciones para detectar mutaciones por empalme de la deshidrogenasa de dihidro-pirimidina.
DE60138531D1 (de) Fluoreszierende im membran interkalierende proben und verfahren zu deren verwendung
FR2756827B1 (fr) Composes synthetiques biepitopiques utilisables comme etalons dans les dosages biologiques de la troponine i
WO2002086505A3 (en) Intracellular analysis
BR0010488A (pt) Tienocicloalqu(en)ilamino-1,3,5-triazinas substituìdas